- Home
- SNTI vs GCDT Comparison
SNTI vs GCDT Comparison
Compare SNTI & GCDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | GCDT |
|---|---|---|
| Founded | 2016 | 1992 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 57.1M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | SNTI | GCDT |
|---|---|---|
| Price | $1.02 | $4.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 288.7K | ★ 433.2K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,130,401.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 216.53 |
| 52 Week Low | $1.02 | $4.15 |
| 52 Week High | $5.10 | $5.85 |
Technical Indicators
Market Signals| Indicator | SNTI | GCDT |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 24.79 |
| Support Level | $1.04 | $4.50 |
| Resistance Level | $1.19 | $5.19 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 10.53 | 0.00 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.